Brazilian Health Regulatory Agency (ANVISA) has authorized Khiron Life Sciences Corp (OTCMKTS:KHRNF) to import medical cannabis products on an individual patient basis. Khiron can now apply for a license to export medical cannabis products to Brazil with this authorization. The company also needs the nod of TSX for the commercialization of cannabis in Brazil.
Khiron achieves a milestone
Director and Chief Executive Officer of Khiron, Alvaro Torres, said the company achieved another milestone on receiving the regulatory nod from ANVISA to introduce its medical cannabis products in the largest Latin American market. It allows the company to serve the patient population in that region. He further said Khiron work towards achieving authorizations in Peru and Colombia and improves its network in Brazil.
A regulatory framework to import medical cannabis
ANVISA has established a regulatory framework that involves a comprehensive procedure for the production and importing the medical cannabis products into Brazil. The medical cannabis products are prescribed by the physicians and marketed through pharmacies. Therefore, patients get safe access to legal medical cannabis products. Cannabis is beneficial for regulating oily skin and helps to fight aging.
The market for medical cannabis
The demand for medical cannabis in Brazil expects to reach 1.4 billion in the next three years. Also, the patient base that comprises patients with chronic conditions in Brazil will increase to 3.4 million. The request for medical cannabis products in the nation almost tripled since 2015. Around 1,100 physicians are prescribing medical cannabis products to the patients.
Chairman of Khiron resigns
Sidney Himmel, chairman of Khiron, has resigned to pursue other interests. Following his resignation, Alvaro will act as interim chairman of the company. Deborah Rosati will head the audit committee.
Khiron formed a JV with Dixie Brands to focus on the development of cannabis products. As per the terms of the pact, Dixie will also engage in the manufacture and distribution of kuida brand CBD cosmeceuticals targeting Hispanic population in the US. The joint venture with Dixie Brands gives Khiron exposure to the US market.
Chris Naprawa is a president at Khiron. Before joining Khiron, he worked as MD at Primary Capital and as a partner at Sprott Capital Partners.
Business intelligence from Akerna Corp (NASDAQ:KERN) Says Liquor Sales are Up 10% Year-over-Year
Post Views: 364 Liquor sales are up 10% year-over-year according to business intelligence from Akerna Corp (NASDAQ:KERN). Red wine took...
Pyxis Tankers Inc. (NASDAQ:PXS) Announce Q1 2020 Financial Results Amid COVID-19 Uncertainties
Post Views: 205 Pyxis tankers Inc. (NASDAQ:PXS) has announced its unaudited financial results for the quarter that ended March 31,...
Innovative Industrial Properties Inc (NYSE:IIPR) Enters Into a Lease Amendment Agreement with Green Leaf
Post Views: 226 With pot being legalized in many countries, the market is likely to get even bigger. As a...
Liberty Leaf Holdings Ltd (OTCMKTS:LIBFD) Takes Over Nova Mentis Biotech Corp And Add Synergies To Its Cannabis Assets In The Wellness And Health Sector
Post Views: 230 Liberty Leaf Holdings Ltd (OTCMKTS:LIBFD) gained access to the psilocybin by acquiring Nova Mentis Biotech Corp. The...
Aleafia Health Inc (OTCMKTS:ALEAF) Begins Cultivation At Its Entire Niagara Facility And Provides Consistent Supplies for Health: Settles Disputes With Aphria
Post Views: 341 Aleafia Health Inc (OTCMKTS:ALEAF) will commence cultivation operations at its whole Niagara facility. It obtained a license...
Pure Capital Calls For Shareholders Meeting of Therapix Biosciences Ltd (NASDAQ:TRPX): Demands For Dismissal Of Board Members
Post Views: 274 Pure Capital called for an emergency meeting of investors of Therapix Biosciences Ltd (NASDAQ:TRPX) to discuss actions...